Emerging resistance in Neisseria meningitidis and Neisseria gonorrhoeae

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 2, 2011, Pages 237-244

  Stefanelli, Paola ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

antibiotic resistance; Neisseria gonorrhoeae; Neisseria meningitidis

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; GENTAMICIN; KANAMYCIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPECTINOMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; CHEMOPROPHYLAXIS; DISEASE DURATION; DRUG SURVEILLANCE PROGRAM; INFECTION CONTROL; MENINGOCOCCOSIS; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GONORRHEA; HUMANS; MENINGOCOCCAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; POPULATION SURVEILLANCE;

EID: 79952177210     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.171     Document Type: Review

References (70)

1. Septimus EJ, Kuper KM. Clinical challenges in addressing resistance to antimicrobial drugs in the twenty-first century. Clin. Pharmacol. Ther. 86, 336-339 (2009).
2. Andersson DI. Persistence of antibiotic resistant bacteria. Curr. Opin. Microbiol. 6, 452-456 (2003).
3. Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol. 9, 461-465 (2006).
4. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9, 1065-1078 (1987).
5. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect. Dis. 5, 115-119 (2005).
6. Gould IM. The epidemiology of antibiotic resistance. Int. J. Antimicrob. Agents. 32(Suppl. 1), S2-S9 (2008).
7. Spellberg B, Guidos R, Gilbert D et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 155-164 (2008).
8. Manchanda V, Gupta S, Bhalla P. Meningococcal disease: history, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention. Indian J. Med. Microbiol. 24, 7-19 (2006). • An extensive overview on meningococcal disease.
9. Brown EM, Fisman DN, Drews SJ et al. Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006. Antimicrob. Agents Chemother. 54, 1016-1021 (2010).
10. Hedberg ST, Olcen P, Fredlund H, Unemo M. Antibiotic susceptibility of invasive Neisseria meningitidis isolates from 1995 to 2008 in Sweden - the meningococcal population remains susceptible. Scand. J. Infect. Dis. 42, 61-64 (2010).
11. du PM, von GA, Cohen C, de Gouveia L, Klugman KP. Neisseria meningitidis intermediately resistant to penicillin and causing invasive disease in South Africa in 2001 to 2005. J. Clin. Microbiol. 46, 3208-3214 (2008).
12. Sosa J, Llanes R, Guzman D, Quintana I, Flores M, Gutierrez O. Typing and susceptibility to penicillin of Neisseria meningitidis isolated from patients in Cuba (1993-1999). Mem. Inst. Oswaldo Cruz 96, 523-525 (2001).
13. Richter SS, Gordon KA, Rhomberg PR, Pfaller MA, Jones RN. Neisseria meningitidis with decreased susceptibility to penicillin: report from the SENTRY antimicrobial surveillance program, North America, 1998-1999. Diagn. Microbiol. Infect. Dis. 41, 83-88 (2001).
14. Antignac A, Kriz P, Tzanakaki G, Alonso JM, Taha MK. Polymorphism of Neisseria meningitidis penA gene associated with reduced susceptibility to penicillin. J. Antimicrob. Chemother. 47, 285-296 (2001).
15. Saez-Nieto JA, Lujan R, Berron S et al. Epidemiology and molecular basis of penicillin-resistant Neisseria meningitidis in Spain: a 5-year history (1985-1989). Clin. Infect. Dis. 14, 394-402 (1992).
16. Spratt BG, Zhang QY, Jones DM, Hutchison A, Brannigan JA, Dowson CG. Recruitment of a penicillin-binding protein gene from Neisseria flavescens during the emergence of penicillin resistance in Neisseria meningitidis. Proc. Natl Acad. Sci. USA 86, 8988-8992 (1989).
17. Spratt BG, Bowler LD, Zhang QY, Zhou J, Smith JM. Role of interspecies transfer of chromosomal genes in the evolution of penicillin resistance in pathogenic and commensal Neisseria species. J. Mol. Evol. 34, 115-125 (1992).
18. Bowler LD, Zhang QY, Riou JY, Spratt BG. Interspecies recombination between the penA genes of Neisseria meningitidis and commensal Neisseria species during the emergence of penicillin resistance in Neisseria meningitidis: natural events and laboratory simulation. J. Bacteriol. 176, 333-337 (1994).
19. Taha MK, Vázquez JA, Hong E et al. Target gene sequencing to characterize the penicillin G susceptibility of Neisseria meningitidis. Antimicrob. Agents Chemother. 51, 2784-2792 (2007).
20. Vazquez JA, Arreaza L, Block C et al. Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob. Agents Chemother. 47, 3430-3434 (2003). •• First multicenter study to set up the best practice for antibiotic susceptibility testing of Neisseria meningitidis.
21. Vazquez JA. Resistance testing of meningococci: the recommendations of the European Monitoring Group on Meningococci. FEMS Microbiol. Rev. 31, 97-100 (2007). •• First recommendations for resistance testing of meningococci.
22. Contoyiannis P, Adamopoulos DA. Letter: penicillin-resistant Neisseria meningitidis. Lancet 1, 462 (1974).
23. Turner PC, Southern KW, Spencer NJ, Pullen H. Treatment failure in meningococcal meningitis. Lancet 335, 732-733 (1990).
24. Casado-Flores J, Osona B, Domingo P, Barquet N. Meningococcal meningitis during penicillin therapy for meningococcemia. Clin. Infect. Dis. 25, 1479 (1997).
25. Fangio P, Desbouchages L, Lachérade JC et al. Neisseria meningitidis C:2b:P1.2,5 with decreased susceptibility to penicillin isolated from a patient with meningitis and purpura fulminans. Eur. J. Clin. Microbiol. Infect. Dis. 24, 140-141 (2005).
26. Wall RA. Meningococcal disease, some issues in treatment. J. Infect. 42, 87-99 (2001).
27. Carter PE, Abadi FJ, Yakubu DE, Pennington TH. Molecular characterization of rifampin-resistant Neisseria meningitidis. Antimicrob. Agents Chemother. 38, 1256-1261 (1994). • First molecular characterization study of rifampicin-resistant meningococci.
28. Nolte O. Rifampicin resistance in Neisseria meningitidis: evidence from a study of sibling strains, description of new mutations and notes on population genetics. J. Antimicrob. Chemother. 39, 747-755 (1997).
29. Stefanelli P, Fazio C, La RG, Marianelli C, Muscillo M, Mastrantonio P. Rifampicin-resistant meningococci causing invasive disease: detection of point mutations in the rpoB gene and molecular characterization of the strains. J. Antimicrob. Chemother. 47, 219-222 (2001).
30. Cooke RP, Riordan T, Jones DM, Painter MJ. Secondary cases of meningococcal infection among close family and household contacts in England and Wales, 1984-1987. Br. Med. J. 298, 555-558 (1989).
31. Yagupsky P, Ashkenazi S, Block C. Rifampicin-resistant meningococci causing invasive disease and failure of chemoprophylaxis. Lancet 341, 1152-1153 (1993).
32. Almog R, Block C, Gdalevich M, Lev B, Wiener M, Ashkenazi S. First recorded outbreaks of meningococcal disease in the Israel Defence Force: three clusters due to serogroup C and the emergence of resistance to rifampicin. Infection 22, 69-71 (1994).
33. Dawson SJ, Fey RE, McNulty CA. Meningococcal disease in siblings caused by rifampicin sensitive and rifampicin resistant strains. Commun. Dis. Public Health 2, 215-216 (1999).
34. Taha MK, Hedberg ST, Szatanik M et al. Multicenter study for defining the breakpoint for rifampicin resistance in Neisseria meningitidis by rpoB sequencing. Antimicrob. Agents Chemother. 54(9), 3651-3658 (2010).
35. Skoczynska A, Alonso JM, Taha MK. Ciprofloxacin resistance in Neisseria meningitidis, France. Emerg. Infect. Dis. 14, 1322-1323 (2008).
36. Enriquez R, Abad R, Salcedo C, Perez S, Vazquez JA. Fluoroquinolone resistance in Neisseria meningitidis in Spain. J. Antimicrob. Chemother. 61, 286-290 (2008).
37. Strahilevitz J, Adler A, Smollan G, Temper V, Keller N, Block C. Serogroup A Neisseria meningitidis with reduced susceptibility to ciprofloxacin. Emerg. Infect. Dis. 14, 1667-1669 (2008).
38. Shultz TR, White PA, Tapsall JW. In vitro assessment of the further potential for development of fluoroquinolone resistance in Neisseria meningitidis. Antimicrob. Agents Chemother. 49, 1753-1760 (2005).
39. Chu YW, Cheung TK, Tung V et al. A blood isolate of Neisseria meningitidis showing reduced susceptibility to quinolones in Hong Kong. Int. J. Antimicrob. Agents. 30, 94-95 (2007).
40. Tzanakaki G, Blackwell CC, Kremastinou J, Kallergi C, Kouppari G, Weir DM. Antibiotic sensitivities of Neisseria meningitidis isolates from patients and carriers in Greece. Epidemiol. Infect. 108, 449-455 (1992).
41. Shultz TR, Tapsall JW, White PA et al. Chloramphenicol-resistant Neisseria meningitidis containing catP isolated in Australia. J. Antimicrob. Chemother. 52, 856-859 (2003).
42. Galimand M, Gerbaud G, Guibourdenche M, Riou JY, Courvalin P. High-level chloramphenicol resistance in Neisseria meningitidis. N Engl. J. Med. 339, 868-874 (1998).
43. Manchanda V, Bhalla P. Emergence of non-ceftriaxone-susceptible Neisseria meningitidis in India. J. Clin. Microbiol. 44, 4290-4291 (2006).
44. King AJ. Penicillin resistance in gonorrhoea. Br. J. Vener. Dis. 36, 34-35 (1960).
45. Reyn A, Schmidt H, Trier M, Bentzon MW. Spectinomycin hydrochloride (Trobicin) in the treatment of gonorrhoea. Observation of resistant strains of Neisseria gonorrhoeae. Br. J. Vener. Dis. 49, 54-59 (1973).
46. Ehret JM, Nims LJ, Judson FN. A clinical isolate of Neisseria gonorrhoeae with in vitro resistance to erythromycin and decreased susceptibility to azithromycin. Sex. Transm. Dis. 23, 270-272 (1996).
47. Evans AJ. Relapse of gonorrhoea after treatment with penicillin or streptomycin. Br. J. Vener. Dis. 42, 251-262 (1966).
48. Tapsall J. Multidrug-resistant Neisseria gonorrhoeae. CMAJ 180, 268-269 (2009).
49. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev. Anti Infect. Ther. 7, 821-834 (2009). •• Relevant overview on the antibiotic resistance issue in gonococci.
50. Takahata S, Senju N, Osaki Y, Yoshida T, Ida T. Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 50, 3638-3645 (2006).
51. Turner A, Gough KR, Leeming JP. Molecular epidemiology of tetM genes in Neisseria gonorrhoeae. Sex. Transm. Infect. 75, 60-66 (1999).
52. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb. Mortal. Wkly Rep. 56, 332-336 (2007).
53. Cole MJ, Chisholm SA, Hoffmann S, Lowndes CM, IsonCA; European Surveillance of Sexually Transmitted Infections Network. European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sex. Transm. Infect. 86, 427-432 (2010).
54. Bala M, Sood S. Cephalosporin resistance in Neisseria gonorrhoeae. J. Glob. Infect. Dis. 2, 284-289 (2010).
55. Tapsall JW. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex. Transm. Infect. 85, 256-258 (2009).
56. Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr. Opin. Infect. Dis. 22, 87-91 (2009).
57. Ison CA, Bindayna KM, Woodford N, Gill MJ, Easmon CS. Penicillin and cephalosporin resistance in gonococci. Genitourin. Med. 66, 351-356 (1990).
58. Tapsall J, Read P, Carmody C et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J. Med. Microbiol. 58, 683-687 (2009).
59. Rosen T, Vandergriff T, Harting M. Antibiotic use in sexually transmissible diseases. Dermatol. Clin. 27, 49-61 (2009).
60. Palmer HM, Young H, Winter A, Dave J. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J. Antimicrob. Chemother. 62, 490-494 (2008).
61. Chisholm SA, Neal TJ, Alawattegama AB, Birley HD, Howe RA, Ison CA. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J. Antimicrob. Chemother. 64, 353-358 (2009).
62. Galarza PG, Alcalá B, Salcedo C et al. Emergence of high level azithromycin-resistant Neisseria gonorrhoeae strain isolated in Argentina. Sex. Transm. Dis. 36, 787-788 (2009).
63. Starnino S, Stefanelli P; Neisseria gonorrhoeae Italian Study Group. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J. Antimicrob. Chemother. 63(6), 1200-1204 (2009).
64. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann. Intern. Med. 148, 606-613 (2008). • Important article summarizing the main issue concerning the impending problem of the depletion of antibiotic treatment for gonorrhoea.
65. Chen PL, Lee HC, Yan JJ et al. High prevalence of mutations in quinolone-resistance-determining regions and mtrR loci in polyclonal Neisseria gonorrhoeae isolates at a tertiary hospital in Southern Taiwan. J. Formos. Med. Assoc. 109, 120-127 (2010).
66. de Vries HJ, van der Helm JJ, Schim van der Loeff MF, van Dam AP. Multidrug-resistant Neisseria gonorrhoeae with reduced cefotaxime susceptibility is increasingly common in men who have sex with men, Amsterdam, The Netherlands. Euro. Surveill. 14(37), pii: 19330 (2009).
67. European Monitoring Group for Meningococci (EMGM) http://neisseria.org/ nm/emgm
68. European Centre for Disease Prevention and Control www.ecdc.europa.eu
69. Performance standards for antimicrobial susceptibility testing, 20th informational supplement www.clsi.org/source/orders/free/m100-s20-u.pdf
70. European Committee on Antimicrobial Susceptibility Testing www.eucast.org